Olga-demetra Biziotis
Hamilton, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
HER2-specific synthetic antigen receptor T cell therapy synergizes with radiotherapy to provide improved antitumor efficacy in non-small cell lung cancer.
Journal: Journal of leukocyte biology
Published: August 22, 2025
Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinoma.
Journal: JHEP reports : innovation in hepatology
Published: August 09, 2024
Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Journal: Radiation oncology (London, England)
Published: April 14, 2024
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α.
Journal: Molecular oncology
Published: February 17, 2023
The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy.
Journal: Communications biology
Published: November 12, 2022
18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer.
Journal: Clinical and translational radiation oncology
Published: October 17, 2022
Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses.
Journal: Translational oncology
Published: June 14, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026